PDBsum entry 6emh

Transferase

PDB id: 6emh

Contents

Protein chains

344 a.a.

Ligands

BME ×3

BGE ×4

EDO ×5

C15 ×2

PEG ×2

GOL ×3

Metals

_CL ×3

Waters ×861

PDB id:

6emh

Name:

Transferase

Title:

Crystal structure of jnk3 in complex with a pyridinylimidazole inhibitor

Structure:

Mitogen-activated protein kinase 10. Chain: a, b, c, d. Synonym: mapk 10,map kinase p49 3f12,stress-activated protein kinase 1b,sapk1b,stress-activated protein kinase jnk3,c-jun n-terminal kinase 3. Engineered: yes

Source:

Homo sapiens. Human. Organism_taxid: 9606. Gene: mapk10, jnk3, jnk3a, prkm10, sapk1b. Expressed in: escherichia coli. Expression_system_taxid: 562

Resolution:

1.76Å R-factor: not given

Authors:

J.T.Macedo,T.Stehle,B.S.Blaum

Key ref:

F.Ansideri et al. (2018). Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3. ACS Omega, 3, 7809-7831. PubMed id: 30087925

Date:

02-Oct-17 Release date: 08-Aug-18

Protein chains

P53779  (MK10_HUMAN) -  Mitogen-activated protein kinase 10 from Homo sapiens

Seq: 464 a.a.

Struc: 344 a.a.

Enzyme reactions

• Enzyme class: E.C.2.7.11.24 - mitogen-activated protein kinase.
• Reaction:
  1. L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H⁺
  2. L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H⁺

Molecule diagrams generated from .mol files obtained from the KEGG ftp site

reference

ACS Omega 3:7809-7831 (2018)

PubMed id: 30087925

Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.

F.Ansideri, J.T.Macedo, M.Eitel, A.El-Gokha, D.S.Zinad, C.Scarpellini, M.Kudolo, D.Schollmeyer, F.M.Boeckler, B.S.Blaum, S.A.Laufer, P.Koch.

ABSTRACT

Starting from known p38α mitogen-activated protein kinase (MAPK) inhibitors, a series of inhibitors of the c-Jun N-terminal kinase (JNK) 3 was obtained. Altering the substitution pattern of the pyridinylimidazole scaffold proved to be effective in shifting the inhibitory activity from the original target p38α MAPK to the closely related JNK3. In particular, a significant improvement for JNK3 selectivity could be achieved by addressing the hydrophobic region I with a small methyl group. Furthermore, additional structural modifications permitted to explore structure-activity relationships. The most potent inhibitor 4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-N-(4-morpholinophenyl)pyridin-2-amine showed an IC₅₀ value for the JNK3 in the low triple digit nanomolar range and its binding mode was confirmed by X-ray crystallography.